Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada
暂无分享,去创建一个
O. Djurdjev | A. Levin | P. Parfrey | M. Canney | P. Birks | Selena Shao | S. Shao
[1] J. Wish. Perspective: Will We Ever Know the Optimal Hgb Level in ESRD? , 2018, Journal of the American Society of Nephrology : JASN.
[2] Björn Eliasson,et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes , 2017, The New England journal of medicine.
[3] J. Sterne,et al. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005–13 , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] Mark S Levenson,et al. Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare. , 2016, JAMA internal medicine.
[5] Validity of Canadian discharge abstract data for hypertension and diabetes from 2002 to 2013. , 2016, CMAJ open.
[6] Chuan-Fen Liu,et al. Decisions about Renal Replacement Therapy in Patients with Advanced Kidney Disease in the US Department of Veterans Affairs, 2000-2011. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[7] A. Collins,et al. Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] J. Carrero,et al. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] K. Rothman,et al. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. , 2016, Journal of the American Society of Nephrology : JASN.
[10] Vincent Mor,et al. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents. , 2015, Health services research.
[11] A. Collins,et al. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] Ahmed A. Al-Jaishi,et al. Canadian Organ Replacement Register (CORR): reflecting the past and embracing the future , 2014, Canadian journal of kidney health and disease.
[13] J. Adamson,et al. Notice , 2012, Kidney International Supplements.
[14] M. Tonelli,et al. Rates of treated and untreated kidney failure in older vs younger adults. , 2012, JAMA.
[15] Marcello Tonelli,et al. The new FDA labeling for ESA--implications for patients and providers. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[16] J. Adamson,et al. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease , 2012 .
[17] A. Garg,et al. A validation study of the Canadian Organ Replacement Register. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[18] C. Charytan. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[19] D. Revicki,et al. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] R. Garrick. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .
[21] S. Solomon,et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.
[22] H. Burger,et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.
[23] Huiman Barnhart,et al. Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.
[24] R. Foley,et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. , 2005, Journal of the American Society of Nephrology : JASN.
[25] A R Nissenson,et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.